drugset / Trial / NCT07085039
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
Phase 2
Recruiting
14 enrolled
University of Pennsylvania
Incyte Corporation · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.
Timeline
- Start
- 2025-12-18
- Primary completion
- 2028-07-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | — | Oral |